AB0736 SEVERITY OF NAIL PSORIASIS SCORE (SNAPS) IS SENSITIVE TO CHANGE IN A COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH ETANERCEPT

Background:

The Severity of Nail Psoriasis Score (SNAPS; range 0-40: scored one point each for the presence of pitting, onycholysis, hyperkeratosis and/or severe nail disease#in each fingernail) has been utilised to collect data regarding psoriatic nail dystrophy in the Bath Psoriatic Arthritis (PsA) Longitudinal cohort for many years. SNAPS has construct validity in PsA with the modified Nail Psoriasis Severity Index (mNAPSI) as a comparator instrument and appears to be more feasible than mNAPSI with excellent reliability1.

Objectives:

We aimed to determine if SNAPS could demonstrate longitudinal sensitivity to change in a cohort of patients treated with biological disease modifying anti-rheumatic drugs (bDMARDs) and therefore be utilized prospectively in observational and clinical trial settings.

Methods:

Patients enrolled in the Bath PsA longitudinal cohort routinely undergo clinical assessments including a 66/68 Swollen and Tender Joint Count (SJC/TJC), Psoriasis Area Severity Index (PASI), Patient Global Assessment (PtGA) and Physician Global Assessment (PhGA), as well as complete patient-reported outcome measures such as the Health Assessment Questionnaire (HAQ) and Dermatology Quality of Life (Derm-QoL). All patients who commenced treatment with Etanercept and had available outcome data at baseline, 3 months and 6 months were included in this retrospective analysis. Baseline demographics were recorded and paired t-tests were utilized to assess the change in SNAPS at 3 and 6 months. The effect size and measurement error of SNAPS in this cohort were measured. Correlations between SNAPS and other outcome measures were assessed using Pearson’s r.

Results:

Fifty-seven patients (32 male and 25 female) with available data were retrospectively analysed. The mean (±SD) age of the cohort and duration of disease was 61.3 (±11.55) and 13.3 (±10.82) years respectively. The mean SNAPS at baseline was 3.7 (±6.13) and improved to 2.0 (3.74, p=0.018) at 3 months and 1.2 (2.40) at 6 months (p=0.001 for change from baseline and p=0.039 for change from month 3). The smallest detectable difference at 3 months for SNAPS in this cohort was 1.35, representing 3.37% of the range of the score (Table 2). The standardised response mean (SRM) was 0.32 at 3 months and 0.44 at 6 months. There was a modest correlation between the improvement in the SNAPS score and the improvement in PASI and Derm QOL at 3 months (r = 0.511 and 0.558 respectively, p=0.001) and 6 months (r= 0.672, p<0.001 and r=0.510, p=0.003 respectively).

Conclusion:

SNAPS demonstrates sensitivity to change in response to treatment with a bDMARD and could be a potential outcome measure for the assessment of treatment efficacy in prospective studies.

References:

[1]Antony A, Hart D, Cavill C, Korendowych E, McHugh N, Lovell C, Tillett W. The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis [abstract].Arthritis Rheumatol.2019; 71 (suppl 10).

Table 1.

Outcomes at Baseline, 3 months and 6 months

Mean (SD) or Median [IQR]Baseline3 Months(p for change from baseline)6 Months(p for change from baseline)PASI (0-72)3.0 (4.80)1.6 (2.12) p=0.011.3 (1.6) p=0.002SNAPS (0-40)3.7 (6.13)2.0 (3.73) p=0.0181.2 (2.39) p=0.001Derm-QoL (0-30)5.7 (7.07)1.95 (3.23) p=0.001 (n=33)1.9(4.72) p=0.037 (n=31)Table 2.

Measurement Error for SNAPS in an Etanercept Cohort

TimeframeStandardised Response MeanStandard Error of MeanSmallest Detectable ChangeSmallest Detectable Change (% of total score)Smallest Detectable DifferenceSmallest Detectable Difference (% of total score)0-3 months0.320.691.914.771.353.370-6 months0.440.742.065.151.463.64

Disclosure of Interests:

Anna Antony: None declared, Sadaf Saeed: None declared, Darren Hart: None declared, Preeti Nair: None declared, Charlotte Cavill: None declared, Eleanor Korendowych: None declared, Neil McHugh: None declared, Christopher Lovell: None declared, William Tillett Grant/research support from: AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, Consultant of: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, MSD, Pfizer Inc, UCB, Speakers bureau: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, Pfizer Inc, UCB

AB0735 SEVERITY OF NAIL PSORIASIS SCORE (SNAPS) DEMONSTRATES LONGITUDINAL CONSTRUCT VALIDITY AGAINST THE MODIFIED NAIL PSORIASIS SEVERITY INDEX (mNAPSI) IN AN OBSERVATIONAL COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS

Background:

Longitudinal observational data on psoriatic nail dystrophy is scarce, in part due to the lack of a validated outcome measure that is feasible in routine care. The Severity of Nail Psoriasis Score (SNAPS; range 0-40: scored one point each for the presence of pitting, onycholysis, hyperkeratosis and/or severe nail disease#in each fingernail) has face validity and has recently demonstrated feasibility, reliability and cross-sectional construct validity against the modified Nail Psoriasis Severity Index (mNAPSI; range 0-130)1.

Objectives:

We aimed to assess the longitudinal construct validity of SNAPS against the mNAPSI and physician nail VAS (PhNVAS), and to determine the effect size and measurement error of these tools.

Methods:

Consenting consecutive patients enrolled in the Bath Psoriatic Arthritis (PsA) longitudinal cohort underwent photography of their fingernails at baseline1and 6 months alongside routine clinical assessments. Dorsal images of individual fingernails were acquired using a tripod mounted DSLR camera. An angled mirror positioned distally aided identification of hyperkeratosis. Photograps were scored using SNAPS, mNAPSI and PhNVAS1. Paired statistical analyses were conducted to assess for change in scores from baseline to follow-up. Pairwise correlations between change in SNAPS and change in mNAPSI and PhyNVAS were assessed using Spearman’s rho. Effect sizes and measurement error were calculated.

Results:

Fifteen patients with a mean (±SD) age of 54.5 (±10.59) were assessed at 6 months. There was a significant reduction in both the mNAPSI and SNAPS scores (p<0.005), with improvements in the most frequently-observed manifestations1i.e. pitting, onycholysis, hyperkeratosis and crumbling (Table 1). No other feature specific to mNAPSI improved over time. There was no significant change using the PhyNVAS. There was a strong correlation between changes in SNAPS and the mNAPSI (Figure 1; rho = 0.838, p<0.001). The correlation between change in SNAPS and PhyNVAS was not statistically significant (rho =0.45, p=0.095) (Figure 1). The change in mNAPSI correlated moderately with the PhNVAS (rho = 0.540, p=0.038). mNAPSI was superior to SNAPS in most parameters of measurement error (Table 2). The mNAPSI and SNAPS had similar effect sizes as measured by the SRM (Table 2).

Conclusion:

SNAPS demonstrates longitudinal construct validity against the mNAPSI in a small observational cohort of PsA patients as evidenced by a strong correlation between the measures, comparable effect sizes and sensitivity to change over time. Whilst measurement error parameters favored the mNAPSI, SNAPS may be a more feasible measure for studying nail disease in cohort studies.

References:

[1]Antony A, Hart D, Cavill C, Korendowych E, McHugh N, Lovell C, Tillett W. The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis [abstract].Arthritis Rheumatol.2019; 71 (suppl 10).

Table 1.

Outcomes at Baseline and at Follow-Up:

OutcomeMean (SD) or Median (IQR) N=15t-test or Wilcoxon Sign Rank test (p-value)BaselineFollow-upSNAPS13.0 [8.00-21.00]5.0 [2.00-11.00]0.002*mNAPSI22.0 [12.00-35.00]6.0 [4.00-15.00]0.001*Physician Nail VAS23.3 (22.90)15.8 (15.22)0.147Physician Global VAS18.0 [10.75-32.75]15.0 [10.00-30.00]0.455Table 2.

Measurement error of SNAPS, mNAPSI, PtNVAS and PhyNVAS

SRMSEMSDCSDC % (% of total score)SDDSDD% (% of total score)SNAPS1.151.716.7216.793.368.40mNAPSI1.153.5113.7410.576.875.29Physician Nail VAS0.404.7118.4714.219.237.10Figure 1.

Correlation between changes in SNAPS and changes in mNAPSI

Disclosure of Interests:

Anna Antony: None declared, Sadaf Saeed: None declared, Darren Hart: None declared, Preeti Nair: None declared, Charlotte Cavill: None declared, Eleanor Korendowych: None declared, Neil McHugh: None declared, Christopher Lovell: None declared, William Tillett Grant/research support from: AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, Consultant of: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, MSD, Pfizer Inc, UCB, Speakers bureau: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, Pfizer Inc, UCB

Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery

Essentials Factor IX (FIX) dosing using body weight frequently results in under and overdosing during surgery. We aimed to establish a population pharmacokinetic (PK) model describing the perioperative FIX levels. Population PK parameter values for clearance and V1 were 284 mL h-170 kg-1 and 5450 mL70 kg-1. Perioperative PK parameters differ from those during non-surgical prophylactic treatment. SUMMARY: Background Hemophilia B is a bleeding disorder characterized by a deficiency of coagulation factor IX (FIX). In the perioperative setting, patients receive FIX concentrates to ensure hemostasis. Although FIX is usually dosed according to bodyweight, under- and overdosing occurs frequently during surgery. Aim The objective was to quantify and explain the interpatient variability of perioperatively administered plasma-derived (pd) and recombinant (r) FIX concentrates. Methods Data were collected from 118 patients (median age, 40 years [range, 0.2-90]; weight, 79 kg [range, 5.3-132]) with moderate (28%) or severe hemophilia B (72%), undergoing 255 surgical procedures. Population pharmacokinetic (PK) parameters were estimated using nonlinear mixed-effect modeling in NONMEM. Results Measured perioperative FIX level vs. time profiles were adequately described using a three-compartment PK model. For a typical 34-year-old patient receiving rFIX, clearance (CL), intercompartmental clearance (Q2, Q3), distribution volume of the central compartment (V1) and peripheral compartments (V2, V3) plus interpatient variability (%CV) were: CL, 284 mL h-170 kg-1 (18%); V1, 5450 mL70 kg-1 (19%); Q2, 110 mL h-170 kg-1; V2, 4800 mL70 kg-1; Q3, 1610 mL h-170 kg-1; V3, 2040 mL70 kg-1. From 0.2 years, CL and V1 decreased 0.89% and 1.15% per year, respectively, until the age of 34 years. Patients receiving pdFIX exhibited a lower CL (11%) and V1 (17%) than patients receiving rFIX. Interpatient variability was successfully quantified and explained. Conclusions The estimated perioperative PK parameters of both pdFIX and rFIX are different from those reported for prophylactic treatment. The developed model may be used to apply PK-guided dosing of FIX concentrates during surgery.

Correction to: A zebrafish model of foxe3 deficiency demonstrates lens and eye defects with dysregulation of key genes involved in cataract formation in humans

The authors noticed that Fig. 5A and B aspect ratios appeared sub-optimal in the online published version. This has now been changed.

Perioperative replacement therapy in haemophilia B: An appeal to "B" more precise

INTRODUCTION

Haemophilia B is caused by a deficiency of coagulation factor IX (FIX) and characterized by bleeding in muscles and joints. In the perioperative setting, patients are treated with FIX replacement therapy to secure haemostasis. Targeting of specified FIX levels is challenging and requires frequent monitoring and adjustment of therapy.

AIM

To evaluate perioperative management in haemophilia B, including monitoring of FIX infusions and observed FIX levels, whereby predictors of low and high FIX levels were assessed.

METHODS

In this international multicentre study, haemophilia B patients with FIX < 0.05 IU mL^-1 undergoing elective, minor or major surgical procedures between 2000 and 2015 were included. Data were collected on patient, surgical and treatment characteristics. Observed FIX levels were compared to target levels as recommended by guidelines.

RESULTS

A total of 255 surgical procedures were performed in 118 patients (median age 40 years, median body weight 79 kg). Sixty percent of FIX levels within 24 hours of surgery were below target with a median difference of 0.22 IU mL^-1 [IQR 0.12-0.36]; while >6 days after surgery, 59% of FIX levels were above target with a median difference of 0.19 IU mL^-1 [IQR 0.10-0.39]. Clinically relevant bleeding complications (necessity of a second surgical intervention or red blood cell transfusion) occurred in 7 procedures (2.7%).

CONCLUSION

This study demonstrates that targeting of FIX levels in the perioperative setting is complex and suboptimal, but although this bleeding is minimal. Alternative dosing strategies taking patient and surgical characteristics as well as pharmacokinetic principles into account may help to optimize and individualize treatment.

Boundary spanning at the science-policy interface: the practitioners' perspectives

Cultivating a more dynamic relationship between science and policy is essential for responding to complex social challenges such as sustainability. One approach to doing so is to "span the boundaries" between science and decision making and create a more comprehensive and inclusive knowledge exchange process. The exact definition and role of boundary spanning, however, can be nebulous. Indeed, boundary spanning often gets conflated and confused with other approaches to connecting science and policy, such as science communication, applied science, and advocacy, which can hinder progress in the field of boundary spanning. To help overcome this, in this perspective, we present the outcomes from a recent workshop of boundary-spanning practitioners gathered to (1) articulate a definition of what it means to work at this interface ("boundary spanning") and the types of activities it encompasses; (2) present a value proposition of these efforts to build better relationships between science and policy; and (3) identify opportunities to more effectively mainstream boundary-spanning activities. Drawing on our collective experiences, we suggest that boundary spanning has the potential to increase the efficiency by which useful research is produced, foster the capacity to absorb new evidence and perspectives into sustainability decision-making, enhance research relevance for societal challenges, and open new policy windows. We provide examples from our work that illustrate this potential. By offering these propositions for the value of boundary spanning, we hope to encourage a more robust discussion of how to achieve evidence-informed decision-making for sustainability.

'Venus trapped, Mars transits': Cu and Fe redox chemistry, cellular topography and in situ ligand binding in terrestrial isopod hepatopancreas

Woodlice efficiently sequester copper (Cu) in ‘cuprosomes' within hepatopancreatic ‘S' cells. Binuclear ‘B’ cells in the hepatopancreas form iron (Fe) deposits; these cells apparently undergo an apocrine secretory diurnal cycle linked to nocturnal feeding. Synchrotron-based µ-focus X-ray spectroscopy undertaken on thin sections was used to characterize the ligands binding Cu and Fe in S and B cells of Oniscus asellus (Isopoda). Main findings were: (i) morphometry confirmed a diurnal B-cell apocrine cycle; (ii) X-ray fluorescence (XRF) mapping indicated that Cu was co-distributed with sulfur (mainly in S cells), and Fe was co-distributed with phosphate (mainly in B cells); (iii) XRF mapping revealed an intimate morphological relationship between the basal regions of adjacent S and B cells; (iv) molecular modelling and Fourier transform analyses indicated that Cu in the reduced Cu⁺ state is mainly coordinated to thiol-rich ligands (Cu–S bond length 2.3 Å) in both cell types, while Fe in the oxidized Fe³⁺ state is predominantly oxygen coordinated (estimated Fe–O bond length of approx. 2 Å), with an outer shell of Fe scatterers at approximately 3.05 Å; and (v) no significant differences occur in Cu or Fe speciation at key nodes in the apocrine cycle. Findings imply that S and B cells form integrated unit-pairs; a functional role for secretions from these cellular units in the digestion of recalcitrant dietary components is hypothesized.

Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade

Tumour-induced dysfunction of cytotoxic T cells in patients with multiple myeloma (MM) may contribute to immune escape and be responsible for the lack of therapeutic efficacy of immune checkpoint blockade. We therefore investigated dysfunctional clonal T cells in MM and demonstrated immunosenescence but not exhaustion as a predominant feature. T-cell clones were detected in 75% of MM patients and their prognostic significance was revalidated in a new post-immunomodulatory drug cohort. The cells exhibited a senescent secretory effector phenotype: KLRG-1+/CD57+/CD160+/CD28-. Normal-for-age telomere lengths indicate that senescence is telomere independent and potentially reversible. p38-mitogen-activated protein kinase, p16 and p21 signalling pathways known to induce senescence were not elevated. Telomerase activity was found to be elevated and this may explain how normal telomere lengths are maintained in senescent cells. T-cell receptor signalling checkpoints were normal but elevated SMAD levels associated with T-cell inactivation were detected and may provide a potential target for the reversal of clonal T-cell dysfunction in MM. Low programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4 expression detected on T-cell clones infers that these cells are not exhausted but suggests that there would be a suboptimal response to immune checkpoint blockade in MM. Our data suggest that other immunostimulatory strategies are required in MM.

Subclinical deformities of the hip are significant predictors of radiographic osteoarthritis and joint replacement in women. A 20 year longitudinal cohort study

OBJECTIVE

Femoroacetabular Impingement (FAI) and Acetabular Dysplasia are common deformities, which have been implicated as a major cause of hip osteoarthritis (OA). We examined whether these subtle deformities of the hip are associated with the development of radiographic OA and total hip replacement (THR) in women.

DESIGN

A population-based, longitudinal cohort of 1003 women underwent pelvis radiographs at years 2 and 20. Alpha Angle, Triangular Index Height, Lateral Centre Edge (LCE) angle and Extrusion Index were measured. An alpha angle of greater than 65° was defined as Cam-type FAI. Radiographic OA and the presence of a THR were then determined at 20 years.

RESULTS

Cam-type FAI was significantly associated with the development of radiographic OA. Each degree increase in alpha angle above 65° was associated with an increase in risk of 5% (Odds Ratio (OR) 1.05 [95% confidence interval (CI) 1.01-1.09]) for radiographic OA and 4% (OR 1.04 [95% CI 1.00-1.08]) for THR. For Acetabular Dysplasia, each degree reduction in LCE angle below 28° was associated with an increase in risk of 13.0% (OR 0.87 [95% CI 0.78-0.96]) for radiographic OA and 18% (OR 0.82 [95% CI 0.75-0.89]) for THR.

CONCLUSIONS

This study demonstrates that Cam-type FAI and mild Acetabular Dysplasia are predictive of subsequent OA and THR in a large female population cohort. These are independent of age, BMI and joint space and significantly improve current predictive models of hip OA development.

Large scale meta-analysis of urinary C-terminal telopeptide, serum cartilage oligomeric protein and matrix metalloprotease degraded type II collagen and their role in prevalence, incidence and progression of osteoarthritis

OBJECTIVE

To evaluate the role of three cartilage-derived biomarkers on osteoarthritis (OA): urinary C-terminal telopeptide (uCTX-II), serum cartilage oligomeric protein (sCOMP), and serum MMP degraded type II collagen (sC2M).

SUBJECTS AND METHODS

Samples from 3582 individuals from the Rotterdam Study, the Genetics osteoArthritis and Progression (GARP), the Chingford Study and the TwinsUK cohort were assayed using enzyme-linked immune sorbent assays. Log10 of concentration levels were correlated with risk of hip, hand and knee OA, hip and knee OA severity and incidence, and progression of knee OA, adjusting for age, gender and body mass index (BMI). Results were meta-analysed to assess overall significance.

RESULTS

After adjusting for covariates, sCOMP was associated with knee OA and hip and knee OA incidence. Furthermore, sC2M was associated with knee OA incidence and progression. After adjustment for multiple tests (Bonferroni P < 0.002) only the association between sCOMP and knee OA remained significant (odds ratio (OR) = 3.26 (95%CI 1.63-10.1) P = 0.0008 for each standard deviation (SD) increase in biomarker levels). Levels of uCTX-II were significantly associated with risk of hand, hip and knee OA, progression and incidence of knee OA. A receiver operating characteristics (ROC) analysis showed a consistent improvement in prediction of knee OA progression from an average area under the curve (AUC) is 0.646 for age, sex and BMI alone to an AUC = 0.668 including uCTX-II for prediction.

CONCLUSIONS

uCTX-II is the most informative biochemical marker for prediction of OA. Both sCOMP and C2M showed some association with OA, thus indicating that they are descriptive of disease activity.

Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance

Despite improved outcomes in multiple myeloma (MM), a cure remains elusive. However, even before the current therapeutic era, 5% of patients survived >10 years and we propose that immune factors contribute to this longer survival. We identified patients attending our clinic, who had survived >10 years (n=20) and analysed their blood for the presence of T-cell clones, T-regulatory cells (Tregs) and T helper 17 (Th17) cells. These results were compared with MM patients with shorter follow-up and age-matched healthy control donors. The frequency of cytotoxic T-cell clonal expansions in patients with <10 years follow-up (MM patients) was 54% (n=144), whereas it was 100% (n=19/19) in the long-survivors (LTS-MM). T-cell clones from MM patients proliferated poorly in vitro, whereas those from LTS-MM patients proliferated readily (median proliferations 6.1% and 61.5%, respectively (P<0.0001)). In addition, we found significantly higher Th17 cells and lower Tregs in the LTS-MM group when compared with the MM group. These results indicate that long-term survival in MM is associated with a distinct immunological profile, which is consistent with decreased immune suppression.

Induction and Desensitization of the c-Fos mRNA Response to Nicotine in Rat Brain

Early rapid response genes such as c-fos are activated in the central nervous system by a variety of agents including psychostimulants. In the present studies, we investigated changes in c-fos mRNA content in several brain regions of the rat in response to nicotine. A single injection of nicotine ip increased the c-fos mRNA content within 30 min and returned toward baseline by 120 min. Significant elevations were induced by 0.5 mg/kg bw nicotine in the medial habenula and by 1.0 mg/kg in the hippocampus, dentate gyrus, and piriform cortex. At 1.0 mg/kg, significantly greater increases in c-fos mRNA levels were present in medial habenula and hippocampus compared to dentate gyrus and in dentate gyrus compared to piriform cortex. Moreover, at 1.0 mg/kg nicotine, increases were significantly less in cerebellar cortex and cingulate gyrus, and these were not dose-dependent. Mecamylamine, a nicotinic cholinergic receptor antagonist, significantly attenuated or eliminated c-fos mRNA response to 1.5 mg/kg nicotine in all regions, except in the cerebellar cortex. Desensitization of the c-fos mRNA response to nicotine was investigated by administering two injections of 2.0 mg/kg nicotine 2 h apart. In the hippocampus, dentate gyrus, and piriform cortex, the first dose of nicotine significantly reduced the c-fos mRNA response to a second dose. The magnitude of desensitization ranged from 43% (piriform cortex) to 81% (hippocampus). In summary, nicotine rapidly elevated the c-fos mRNA content in several rat brain regions. The sensitivity of this response to nicotine and development of desensitization differed among the regions.

CMRF44+ Dendritic Cells from Peripheral Blood Stem Cell Harvests of Patients with Myeloma as Potential Cellular Vectors for Idiotype Vaccination

The optimal conditions required to harvest dendritic cells (DC) for immunotherapy were investigated in a series of preliminary investigations using peripheral blood stem cell (PBSC) harvests and blood from patients with myeloma. There was no difference in the number of DC (CMRF44+, CD19-, CD14-) in PBSC mobilized with G-CSF (mean 0.28%, n = 7) compared with GM-CSF (mean 0.24%, n = 6) and apheresis itself did not concentrate DC. In longitudinal studies (n = 10), the peak DC count (day 12 post PBSC harvest) did not correlate with the peak CD34+ cell count or white cell count. A simple affinity purification of DC resulted in a mean 63-fold purification. Affinity enriched suspensions from normal blood contained more DC (mean = 18.8%; n = 5) than those from patients with myeloma (mean = 9.9%; n = 13). The percentage of DC with a lymphoid phenotype (CD11c-, CDw123hi+) was significantly higher in G-CSF mobilized PBSC harvests (22.7%; n = 6) than in peripheral blood samples from patients with myeloma (7.0%; n = 13; p = 0.01). DC endocytosis was normal and did not change throughout the course of the disease. Neither DC numbers nor subsets changed significantly between days 1 and 3 of culture. Current mobilization procedures, optimized for PBSC, need to be altered when harvesting DC.

A meta-analysis of interleukin-6 promoter polymorphisms on risk of hip and knee osteoarthritis

OBJECTIVE

Interleukin-6 is a pro-inflammatory cytokine involved in the pathogenesis of osteoarthritis (OA). We investigated the role of two single nucleotide polymorphisms (SNPs) mapping to the promoter of the IL-6 gene on genetic susceptibility to hip and knee OA.

METHODS

The -174G/C (rs1800795) and -597G/A (rs1800797) SNPs, implicated in the literature in risk of hip and hand OA, were genotyped in 2511 controls, 1101 hip OA cases and 1904 knee OA cases from four cohorts from the UK and Estonia. Data were analysed in conjuntion with published data on rs1800797 from the Genetics of OA and Lifestyle study (UK) on 791 controls, 1034 knee and 997 hip OA cases and rs1800795 data on 75 hip OA cases and 96 controls from Italy. Cases included both radiographic OA only and radiographic and symptomatic OA. Fixed and random-effects meta-analysis models were tested.

RESULTS

No significant association was found with hip OA or knee OA with either SNP nor with the haplotypes formed by them. For individual SNPs the smallest P-value for hip OA was observed using a random-effects model for rs1800795 OR(Gallele)=1.066 (95% CI 0.89-1.28) P<0.49, and significant heterogeneity between cohorts (I(2)=65%, P<0.034) was detected. For knee OA the smallest P-value was seen for rs1800797 OR(Aallele)=1.055 (95%CI 0.98-1.12) P<0.18, no significant heterogeneity was observed (I(2)=0%, P<0.68).

CONCLUSIONS

Our data do not support a role for the -174 and -597 IL-6 promoter polymorphisms in genetic susceptibility to knee or hip OA in Caucasian populations.

Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer

T-cell receptor (TCR) gene transfer is an attractive strategy to generate antigen-specific T-cells for adoptive immunotherapy of cancer and chronic viral infection. However, current TCR gene transfer protocols trigger T-cell differentiation into terminally differentiated effector cells, which likely have reduced ability to mediate disease protection in vivo. We have developed a lentiviral gene transfer strategy to generate TCR-transduced human T-cells without promoting T-cell differentiation. We found that a combination of interleukin-15 (IL15) and IL21 facilitated lentiviral TCR gene transfer into non-proliferating T-cells. The transduced T-cells showed redirection of antigen specificity and produced IL2, IFNgamma and TNFalpha in a peptide-dependent manner. A significantly higher proportion of the IL15/IL21-stimulated T-cells were multi-functional and able to simultaneously produce all three cytokines (P<0.01), compared with TCR-transduced T-cells generated by conventional anti-CD3 plus IL2 stimulation, which primarily secreted only one cytokine. Similarly, IL15/IL21 maintained high levels of CD62L and CD28 expression in transduced T-cells, whereas anti-CD3 plus IL2 accelerated the loss of CD62L/CD28 expression. The data demonstrate that the combination of lentiviral TCR gene transfer together with IL15/IL21 stimulation can efficiently redirect the antigen specificity of resting primary human T-cells and generate multi-functional T-cells.

A genome-wide association study suggests that a locus within the ataxin 2 binding protein 1 gene is associated with hand osteoarthritis: the Treat-OA consortium

To identify the susceptibility gene in hand osteoarthritis (OA) the authors used a two-stage approach genome-wide association study using two discovery samples (the TwinsUK cohort and the Rotterdam discovery subset; a total of 1804 subjects) and four replication samples (the Chingford Study, the Chuvasha Skeletal Aging Study, the Rotterdam replication subset and the Genetics, Arthrosis, and Progression (GARP) Study; a total of 3266 people). Five single-nucleotide polymorphisms (SNPs) had a likelihood of association with hand OA in the discovery stage and one of them (rs716508), was successfully confirmed in the replication stage (meta-analysis p = 1.81×10⁻⁵). The C allele conferred a reduced risk of 33% to 41% using a case–control definition. The SNP is located in intron 1 of the A2BP1 gene. This study also found that the same allele of the SNP significantly reduced bone density at both the hip and spine (p<0.01), suggesting the potential mechanism of the gene in hand OA might be via effects on subchondral bone. The authors' findings provide a potential new insight into genetic mechanisms in the development of hand OA.

National reference doses for common radiographic, fluoroscopic and dental X-ray examinations in the UK

The National Patient Dose Database (NPDD) is maintained by the Radiation Protection Division of the Health Protection Agency. The latest review of the database analysed the data collected from 316 hospitals over a 5-year period to the end of 2005. The information supplied amounted to a total of 23 000 entrance surface dose measurements and 57 000 dose-area product measurements for single radiographs, and 208 000 dose-area product measurements along with 187 000 fluoroscopy times for diagnostic examinations or interventional procedures. In addition, patient dose data for dental X-ray examinations were included for the first time in the series of 5-yearly reviews. This article presents a summary of a key output from the NPDD - national reference doses. These are based on the third quartile values of the dose distributions for 30 types of diagnostic X-ray examination and 8 types of interventional procedure on adults, and for 4 types of X-ray examination on children. The reference doses are approximately 16% lower than the corresponding values in the previous (2000) review, and are typically less than half the values of the original UK national reference doses that were derived from a survey in the mid-1980s. This commentary suggests that two of the national reference doses from the 2000 review be retained as diagnostic reference levels because the older sample size was larger than for the 2005 review. No clear evidence could be found for the use of digital imaging equipment having a significant effect on dose.

Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study

BACKGROUND

Osteoporosis is diagnosed by the measurement of bone mineral density, which is a highly heritable and multifactorial trait. We aimed to identify genetic loci that are associated with bone mineral density.

METHODS

In this genome-wide association study, we identified the most promising of 314 075 single nucleotide polymorphisms (SNPs) in 2094 women in a UK study. We then tested these SNPs for replication in 6463 people from three other cohorts in western Europe. We also investigated allelic expression in lymphoblast cell lines. We tested the association between the replicated SNPs and osteoporotic fractures with data from two studies.

FINDINGS

We identified genome-wide evidence for an association between bone mineral density and two SNPs (p<5x10(-8)). The SNPs were rs4355801, on chromosome 8, near to the TNFRSF11B (osteoprotegerin) gene, and rs3736228, on chromosome 11 in the LRP5 (lipoprotein-receptor-related protein) gene. A non-synonymous SNP in the LRP5 gene was associated with decreased bone mineral density (rs3736228, p=6.3x10(-12) for lumbar spine and p=1.9x10(-4) for femoral neck) and an increased risk of both osteoporotic fractures (odds ratio [OR] 1.3, 95% CI 1.09-1.52, p=0.002) and osteoporosis (OR 1.3, 1.08-1.63, p=0.008). Three SNPs near the TNFRSF11B gene were associated with decreased bone mineral density (top SNP, rs4355801: p=7.6x10(-10) for lumbar spine and p=3.3x10(-8) for femoral neck) and increased risk of osteoporosis (OR 1.2, 95% CI 1.01-1.42, p=0.038). For carriers of the risk allele at rs4355801, expression of TNFRSF11B in lymphoblast cell lines was halved (p=3.0x10(-6)). 1883 (22%) of 8557 people were at least heterozygous for these risk alleles, and these alleles had a cumulative association with bone mineral density (trend p=2.3x10(-17)). The presence of both risk alleles increased the risk of osteoporotic fractures (OR 1.3, 1.08-1.63, p=0.006) and this effect was independent of bone mineral density.

INTERPRETATION

Two gene variants of key biological proteins increase the risk of osteoporosis and osteoporotic fracture. The combined effect of these risk alleles on fractures is similar to that of most well-replicated environmental risk factors, and they are present in more than one in five white people, suggesting a potential role in screening.

Analysis of multidisciplinary lung cancer practice

BACKGROUND

The aim of this study was to describe the activity of a lung cancer multidisciplinary clinic (MDC) and examine whether this model of clinical practice results in adherence to best-practice guidelines.

METHODS

Prospective analysis of demographic and clinical data in 431 patients referred to a lung cancer MDC for the management of known or suspected thoracic malignancy. Adherence was documented to clinically relevant guideline recommendations concerning timely and evidence-based lung cancer management.

RESULTS

Of 431 patients, 257 were diagnosed with primary lung cancer, mean age 68 years, 70% men and 90% current smokers or ex-smokers. Only 21% were referred with known malignancy and 28% were asymptomatic. Overall, 51% had stages I and II non-small-cell lung cancer, with this bias towards early-stage disease greatest in patients from rural areas. Histological confirmation of lung cancer was obtained in 92%. There was a high rate of adherence to international guideline recommendations concerning timely lung cancer diagnosis, staging and treatment implementation. Similarly, there was adherence to selected key evidence based recommendations for lung cancer management contained in national guidelines.

CONCLUSION

Within a MDC, patients receive timely diagnosis, staging and treatment according to evidence-based guideline recommendations. The high proportion of patients receiving active treatment has implications for resource allocation. There is a referral bias towards patients with early non-small-cell lung cancer, particularly in rural patients, suggesting that further education about advances in metastatic lung cancer management is required. This study would support the establishment of regional lung cancer services with links to fully resourced MDC.